New Developments in Factor Replacement Therapy in the Treatment of Hemophilia

This activity has expired.
Release Date: August 15, 2016
Expiration Date: August 15, 2017
Estimated Time to Complete Activity: 60
Minimum System Requirements:
  • Internet Explorer 7 (or higher)
  • Mozilla Firefox 4 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 6.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience

This activity has been designed to meet the educational needs of hematologists, HEM/ONCs, pediatricians, registered nurses, and hemophilia treatment center staff, registered with the Blood CME Center, who are involved in the comprehensive care of people with hemophilia (PWH).

Statement of Need/Program Overview

Optimized outcome and best use of available resources is expected from individualization of therapy regimens, which comprises the individuals bleeding pattern, condition of the musculoskeletal system, level of physical activity, the pharmacokinetic profile of the substituted coagulation factor, and most recently includes novel products with extended half-lives. This Clinical Consults review provides new data, expert opinion, and perspective about implementing programs to reduce risk and improve outcomes in PWH.

Educational Objectives
After participating in this activity, participants should better be able to:
  • Review new data and expert perspectives about the pharmacokinetic (PK) characteristics of coagulation factor concentrates (CFCs) in the treatment of hemophilia
  • Compare clinical data and expert perspectives about novel CFCs in the treatment of hemophilia
  • Initiate discussions with hemophilia patients/caregivers about the risks and benefits of transitioning to newer CFCs
  • Implement individualized hemophilia treatment strategies tailored to individual PK responses and individual patient characteristics
Presenting Faculty
Robert Francis Sidonio Jr, MD, MSc
Assistant Professor of Pediatrics
Associate Director of Hemostasis and Thrombosis
Aflac Cancer and Blood Disorders Center
Emory University/Children’s Healthcare of Atlanta
Atlanta, GA

Shannon L. Meeks, MD
Associate Professor of Pediatrics
Aflac Cancer and Blood Disorders Center
Emory University/Children’s Healthcare of Atlanta
Atlanta, GA

Christine Guelcher, MS, APRN, PPCNP-BC
Pediatric Nurse Practitioner
Center for Cancer and Blood Disorders
Children’s National Health System
Washington, DC

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.
Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Method of Participation
During the period of August 15, 2016, through August 15, 2017, participants must:

  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form
A statement of credit will be issued automatically upon successfully completing the post-activity survey with a score of 75% or better and submitting the activity evaluation.

Fee Information
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Robert Francis Sidonio Jr, MD, MSc

Consulting Fees: Biogen Idec, CSL Behring, Baxalta, Pfizer and Novo Nordisk.

Shannon L. Meeks, MD

Consulting Fees: Biogen Idec, CSL Behring, Bayer, Baxalta and Grifols. Contracted Research: Pfizer

Christine Guelcher, MS, APRN, PPCNP-BC

Consulting Fees: Baxalta, Biogen Idec, Grifols, Octapharma, Novo Nordisk. Fees for Non-CME/CE Services: Novo Nordisk, Baxalta, Solution Sight and NHF

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP

Have no real or apparent conflicts of interest to report.

Educational Concepts in Medicine: Patrick J. Crowley, MBA, President/CEO; Jodi Andrews, Vice President, Operations; Larry Rosenberg, PhD, Medical Writer Have no real or apparent conflicts of interest to report.

Media
Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc